Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Market Outperform Rating from JMP Securities

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research note issued on Monday, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. JMP Securities’ target price suggests a potential upside of 426.32% from the company’s previous close.

Several other research firms also recently weighed in on MRNS. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 18th. Truist Financial reissued a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research note on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $1.90 on Monday. The company has a market cap of $104.37 million, a P/E ratio of -0.72 and a beta of 1.13. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The firm’s 50-day moving average price is $1.39 and its 200-day moving average price is $2.68. Marinus Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period in the prior year, the business posted ($0.61) EPS. As a group, equities analysts anticipate that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 85,455 shares during the last quarter. Vanguard Group Inc. lifted its position in Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after buying an additional 132,689 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth $813,000. Hussman Strategic Advisors Inc. grew its holdings in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth $553,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.